Insider Selling: Septerna (NASDAQ:SEPN) Insider Sells $76,622.04 in Stock

Septerna, Inc. (NASDAQ:SEPN) insider Samira Shaikhly sold 2,178 shares of the firm’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $35.18, for a total value of $76,622.04. Following the sale, the insider owned 793 shares in the company, valued at $27,897.74. The trade was a 73.31% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Samira Shaikhly also recently made the following trade(s):

• On Friday, June 12th, Samira Shaikhly sold 6,250 shares of Septerna stock. The shares were sold at an average price of $35.08, for a total value of $219,250.00.
• On Monday, June 1st, Samira Shaikhly sold 5,935 shares of Septerna stock. The shares were sold at an average price of $28.93, for a total value of $171,699.55.
• On Tuesday, May 26th, Samira Shaikhly sold 11,798 shares of Septerna stock. The shares were sold at an average price of $30.06, for a total value of $354,647.88.

Septerna Price Performance

NASDAQ:SEPN opened at $34.00 on Friday. The company has a market capitalization of $1.53 billion, a price-to-earnings ratio of -41.97 and a beta of 2.28. The business has a 50 day moving average of $29.90 and a 200 day moving average of $27.61. Septerna, Inc. has a 1-year low of $10.62 and a 1-year high of $37.99.

Septerna (NASDAQ:SEPN) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.23. The business had revenue of $26.52 million for the quarter, compared to analysts’ expectations of $16.98 million. Septerna had a negative net margin of 49.88% and a negative return on equity of 12.72%. As a group, sell-side analysts anticipate that Septerna, Inc. will post -1.59 EPS for the current year.

Analysts Set New Price Targets

SEPN has been the topic of a number of analyst reports. Truist Financial lifted their target price on shares of Septerna from $35.00 to $43.00 and gave the stock a “buy” rating in a research report on Wednesday. Wall Street Zen lowered shares of Septerna from a “buy” rating to a “hold” rating in a research report on Saturday, March 14th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of Septerna in a report on Wednesday. Cantor Fitzgerald reissued an “overweight” rating and issued a $60.00 target price on shares of Septerna in a research note on Tuesday, March 10th. Finally, Stifel Nicolaus assumed coverage on Septerna in a report on Friday, May 1st. They set a “buy” rating and a $43.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $45.89.

Institutional Investors Weigh In On Septerna

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. boosted its position in Septerna by 86.6% during the 4th quarter. Goldman Sachs Group Inc. now owns 2,715,129 shares of the company’s stock valued at $75,698,000 after buying an additional 1,260,409 shares during the period. Vanguard Group Inc. raised its stake in shares of Septerna by 7.4% during the third quarter. Vanguard Group Inc. now owns 1,518,757 shares of the company’s stock valued at $28,568,000 after acquiring an additional 104,394 shares during the last quarter. Avoro Capital Advisors LLC raised its stake in shares of Septerna by 8.1% during the third quarter. Avoro Capital Advisors LLC now owns 1,337,500 shares of the company’s stock valued at $25,158,000 after acquiring an additional 100,000 shares during the last quarter. ADAR1 Capital Management LLC boosted its holdings in shares of Septerna by 38.9% during the third quarter. ADAR1 Capital Management LLC now owns 1,176,491 shares of the company’s stock worth $22,130,000 after purchasing an additional 329,264 shares during the period. Finally, Janus Henderson Group PLC purchased a new stake in shares of Septerna during the first quarter worth about $21,334,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.